Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

10 Oct 2019 07:00

RNS Number : 3525P
Polar Capital Holdings PLC
10 October 2019
Β 

10 October 2019

Β 

Polar Capital Holdings plc

AuM Update

Β 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its quarterly update of its unaudited statement of its Assets under Management ("AuM").

Β 

Β 

Group AuMΒ (unaudited)

Β 

Polar Capital reports that as at 30 September 2019 its AuM were Β£14.3bn compared to Β£13.8bn at the end of March 2019, an increase of 3% over the period. During the period, AuM increased by Β£467m which comprised net outflows of Β£448m offset by an increase of Β£915m related to market movement and fund performance.

Β 

AuM movement in six months

to 30 September 2019

Long only

funds

Alternative funds

Total

AUM at 1 April 2019

Β£12,529m

Β£1,306m

Β£13,835m

Net subscriptions / (redemptions)

Β£(560)m

Β£112m

Β£(448)m

Market movement and

performance

Β£868m

Β£47m

Β£915m

Total AuM at 30 September 2019

Β£12,837m

Β£1,465m

Β£14,302m

Β 

Β 

Net performance fees (unaudited)

Β 

The table below sets out the position relating to net performance fee profits due to the Group (after the deduction of staff interests) as a product of accrued performance fees in funds managed by the Group three months before the strike point of such performance fee receipts. The majority of the Group's performance fees crystallise in the second half of the financial year.

Β 

Performance fees

net of staff allocations

Six months to

30 Sept 18

Β 

Β 

Year to

31 Mar 19

(year-end)

Β 

Six months to

30 Sept 19

Β 

Β 

Received

Β 

Β£5.5m

Β£24.0m

Β£3.3m

Accrued but not yet earned in funds with year ends on or before the financial year end

Β£27.0m

n/a

Β£0.9m*

Total net performance fee profits

Β£32.5m

Β£24.0m

Β 

Β£4.2m*

Β 

Β 

*the figures are reduced by Β£2m of net performance fee distributions that relate to prior accounting periods that IFRS require to be deducted from this year's receipts.

Β 

Β 

Β 

As is usual at the time of releasing this update, three months before the crystallisation of performance fees, we disclose the profits that could be due to Polar as a function of the amount of accrued performance fees in our funds as at the end of September. There is no certainty that the fees will be sustained over the next quarter, as performance fee receipts are extremely volatile.

Β 

Gavin Rochussen, Chief Executive, commented:

Β 

"The last quarter has been a challenging period with net outflows of Β£598m following the Β£150m of net inflows in the previous quarter.

Β 

"As communicated at the time of releasing our year-end results in June, the Japan team has undergone changes following the departure of the long-standing manager of our Japan Fund. The team is focused on the Japan Value Fund which has compelling performance and will benefit from greater AuM following the imminent merger of the two funds. Net outflows in the six months from the Japan Fund following the communication of the manager departure and fund merger have been Β£400m. As at 30 September, the Japanese equities team was managing Β£314m.

Β 

"In the six months, two long-standing clients redeemed in excess of Β£500m from two of our highly rated funds, the Polar Capital Technology Fund and the Polar Capital Healthcare Opportunities Fund to take profits and reduce risk in their underlying client portfolios. This has provided the Technology and Healthcare strategies with additional capacity where the demand for their funds is robust.

Β 

"Notwithstanding the Β£900m headwind created by the Japan Fund redemptions and the client redemption from Technology and Healthcare, it is reassuring that, despite the economic and political uncertainty over the last six months, we have had net inflows into the majority of our funds including: Global Insurance, UK Value, European Income and Emerging Market and Asia with positive net inflows of Β£112m into our alternative fund range which includes our Convertibles and UK Absolute products.

Β 

"While accrued performance fees are materially less than the previous year, fees are volatile, and the position three months ago was more in line with last year. There are still three months to the end of the calendar year when performance fees crystallise. We remain confident that our active fundamental fund strategies will continue to deliver above average returns over the long term for our clients."

Β 

Β 

For further information please contact:

Β 

Polar Capital

Gavin Rochussen (Chief Executive)John Mansell (Executive Director)

Samir Ayub (Finance Director)

Β 

Β 

+44 (0)20 7227 2700

Numis Securities Limited - Nomad and Joint Broker

Charles Farquhar

Stephen Westgate

Kevin Cruickshank (QE)

+44 (0)20 7260 1000

Β 

Β 

Peel Hunt LLP - Joint Broker

Guy Wiehahn

Andrew Buchanan

Β 

+44 (0)20 7418 8893

Β 

Camarco

Ed Gascoigne-Pees

Monique Perks

Β 

Β 

+44 (0)20 3757 4995

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
UPDMLBATMBJMBAL
Date   Source Headline
4th Feb 20199:43 amRNSBlock listing Interim Review
1st Feb 201911:41 amRNSTotal Voting Rights
29th Jan 20194:41 pmRNSSecond Price Monitoring Extn
29th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20195:45 pmRNSIssue of Equity
28th Jan 20195:30 pmRNSDirector/PDMR Shareholding
10th Jan 201910:19 amRNSDirector/PDMR Shareholding
10th Jan 20197:00 amRNSAUM Update
2nd Jan 20199:49 amRNSTotal Voting Rights
12th Dec 20184:00 pmRNSIssue of Equity
27th Nov 20184:40 pmRNSSecond Price Monitoring Extn
27th Nov 20184:35 pmRNSPrice Monitoring Extension
26th Nov 20187:00 amRNSUnaudited Interim Results
22nd Nov 20185:00 pmRNSDirectorate Change
5th Nov 20187:01 amRNSNotice of Results
5th Nov 20187:00 amRNSChange of Nominated Adviser and Broker
1st Nov 20187:00 amRNSTotal Voting Rights
25th Oct 20185:26 pmRNSIssue of Equity
24th Oct 20184:52 pmRNSDirector/PDMR Shareholding
17th Oct 20185:49 pmRNSIssue of Equity
15th Oct 201812:38 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
12th Oct 20182:52 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
11th Oct 20184:42 pmRNSIssue of Equity
11th Oct 20187:01 amRNSCrystallisation of business unit & issue of shares
11th Oct 20187:00 amRNSAUM Update
3rd Oct 201810:24 amRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
19th Sep 201811:52 amRNSForm 8.3 - Jardine Lloyd Thompson Group
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
17th Aug 20189:27 amRNSDirectorate Change
6th Aug 20187:00 amRNSBlock listing Interim Review
1st Aug 20187:00 amRNSTotal Voting Rights
31st Jul 20185:57 pmRNSIssue of Equity
31st Jul 201811:29 amRNSDirector/PDMR Shareholding
25th Jul 20183:38 pmRNSDirectorate Change
25th Jul 20183:26 pmRNSResult of AGM
19th Jul 201811:13 amRNSForm 8.3 - Consort Medical Plc
18th Jul 20184:21 pmRNSDirector/PDMR Shareholding
18th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
17th Jul 201810:58 amRNSForm 8.3 - Consort Medical Plc
16th Jul 20183:44 pmRNSDirector/PDMR Shareholding
12th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
12th Jul 20187:00 amRNSAuM Update
11th Jul 201811:06 amRNSForm 8.3 - Consort Medical Plc
3rd Jul 20186:27 pmRNSHolding(s) in Company
3rd Jul 20186:20 pmRNSIssue of Equity
3rd Jul 201812:07 pmRNSForm 8.3 - Consort Medical Plc
2nd Jul 201810:23 amRNSTotal Voting Rights
29th Jun 20187:00 amRNSBlock Listing Application
28th Jun 20185:55 pmRNSAnnual Financial Report
25th Jun 20187:00 amRNSGroup Audited Results for year ended 31 March 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.